Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
3.160
+0.010 (0.32%)
Jun 22, 2026, 4:00 PM EDT - Market closed
Esperion Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 156.16 | 167.85 | 144.76 | 82.25 | 124.78 | 208.89 |
Short-Term Investments | - | - | - | - | 42.09 | 50.44 |
Cash & Short-Term Investments | 156.16 | 167.85 | 144.76 | 82.25 | 166.86 | 259.33 |
Cash Growth | 36.22% | 15.95% | 76.00% | -50.71% | -35.66% | -14.96% |
Accounts Receivable | 132.35 | 140.19 | 80.14 | 48.49 | 33.73 | 22.93 |
Inventory | 104.21 | 105.12 | 94.49 | 65.62 | 35.2 | 34.39 |
Other Current Assets | 66.74 | 49.4 | 18.6 | 4.7 | 10.89 | 12.31 |
Total Current Assets | 459.46 | 462.57 | 338 | 201.07 | 246.68 | 328.97 |
Net Property, Plant & Equipment | 3.01 | 3.26 | 5.77 | 4.68 | 1.2 | 2.56 |
Other Intangible Assets | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
Other Long-Term Assets | - | - | - | - | - | 50 |
Total Assets | 462.53 | 465.89 | 343.82 | 205.8 | 247.94 | 381.59 |
Accounts Payable | 68.41 | 65.07 | 51.65 | 31.72 | 23.04 | 17.56 |
Accrued Expenses | 105.98 | 111.57 | 81.16 | 62.72 | 40.62 | 37.42 |
Short-Term Debt | - | - | 54.58 | - | - | - |
Current Portion of Leases | 1.7 | 2.1 | 2.74 | 1.55 | 0.38 | 1.39 |
Unearned Revenue | 43.53 | 34.48 | 8.52 | 25.4 | 3.51 | 5.68 |
Other Current Liabilities | 80.75 | 87.6 | 47.59 | 34.83 | 24.76 | 11.3 |
Total Current Liabilities | 300.36 | 300.81 | 246.23 | 156.22 | 92.31 | 73.35 |
Long-Term Debt | 250.07 | 249.48 | 237.72 | 261.6 | 259.9 | 258.28 |
Long-Term Leases | 0.86 | 0.65 | 2.57 | 3.02 | 0.67 | 0.52 |
Other Long-Term Liabilities | 219.17 | 216.91 | 246.02 | 239.95 | 218.85 | 246.38 |
Total Long-Term Liabilities | 470.1 | 467.04 | 486.31 | 504.57 | 479.41 | 505.18 |
Total Liabilities | 770.46 | 767.85 | 732.54 | 660.79 | 571.72 | 578.53 |
Common Stock | 0.26 | 0.25 | 0.2 | 0.12 | 0.08 | 0.06 |
Treasury Stock | -55 | -55 | -55 | -55 | -55 | -55 |
Additional Paid-in Capital | 1,396 | 1,377 | 1,267 | 1,149 | 1,071 | 964.4 |
Accumulated Other Comprehensive Income | - | - | - | - | -0 | -0.03 |
Retained Earnings | -1,649 | -1,624 | -1,601 | -1,549 | -1,340 | -1,106 |
Shareholders' Equity | -307.93 | -301.97 | -388.72 | -454.99 | -323.78 | -196.94 |
Total Liabilities & Equity | 462.53 | 465.89 | 343.82 | 205.8 | 247.94 | 381.59 |
Total Debt | 252.63 | 252.23 | 297.6 | 266.17 | 260.95 | 260.2 |
Net Cash (Debt) | -96.47 | -84.38 | -152.84 | -183.92 | -94.09 | -0.86 |
Net Cash Per Share | -0.41 | -0.41 | -0.82 | -1.78 | -1.42 | -0.03 |
Book Value | -307.93 | -301.97 | -388.72 | -454.99 | -323.78 | -196.94 |
Book Value Per Share | -1.32 | -1.45 | -2.08 | -4.41 | -4.88 | -6.81 |
Tangible Book Value | -307.99 | -302.02 | -388.78 | -455.05 | -323.83 | -197 |
Tangible Book Value Per Share | -1.32 | -1.45 | -2.08 | -4.41 | -4.88 | -6.82 |